Abstract
First report of t(8;21)(q22;q22) in a patient with CLL. RUNX1‐RUNX1T1 fusion gene resulting from the translocation may have played a role in the prolymphocytic transformation.
Keywords: hematology, oncology
First report of t(8;21)(q22;q22) in a patient with CLL. RUNX1‐RUNX1T1 fusion gene resulting from the translocation may have played a role in the prolymphocytic transformation.
An 81‐year‐old man with 20‐year history of chronic lymphoid leukemia/small lymphocytic lymphoma (CLL/SLL) with trisomy 12 presented with weakness. CBC showed WBC 60.2 × 109 cells/L, hemoglobin 13.2 g/dL, and platelet count of 95 × 109 cells/L. Imaging revealed lymphadenopathy and splenomegaly. Peripheral blood and marrow aspirate showed prolymphocytes (Figure 1A‐B). Cytogenetics showed a t(8;21)(q22;q22.1) and trisomy 12 in six out of twenty metaphases (Figure 2A).
FIGURE 1.
Peripheral blood showing prolymphocytic transformation to CLL cells (1A) and bone marrow biopsy with transformation of CLL to prolymphocytic leukemia (1B)
FIGURE 2.
Cytogenetics showed an abnormal male karyotype with six out of twenty metaphases showing a translocation between chromosomes 8 and 21 in addition to trisomy 12 (2A)
Chronic lymphoid leukemia/small lymphocytic lymphoma is an indolent lymphoproliferative disorder that can transform into an aggressive malignancy with unfavorable prognosis in about 5%‐10% of patients. 1 , 2 Transformation can be prolymphocytic or into diffuse large cell lymphoma, also known as Richter transformation. 3 , 4 , 5 , 6 , 7 There are no known cases to date of transformation to prolymphocytic leukemia with t(8;21)(q22;q22.1), which is typically observed in acute myeloid leukemia. 8 , 9 The t(8;21) results in a fusion oncoprotein between RUNX1 and ETO. 10 RUNX1‐RUNX1T1 fusion leads to disruption of normal function of the core‐binding factor in the regulation of hematopoietic differentiation and maturation. Given that RUNX1 is critical for maturation of a wide range of hematopoietic stem cells and has been implicated in pathogenesis of several myeloid and lymphoid malignancies, we postulate that the t(8;21)(q22;q22.1) played a role in prolymphocytic transformation in this patient. 11 , 12 , 13
CONFLICT OF INTEREST
None.
AUTHOR CONTRIBUTIONS
I, MB: am the first author of this publication, and KRK: is the advising author of this publication.
ACKNOWLEDGMENTS
Vikas Bhushan, MD for assistance and support as well as access to patient file. Published with written consent of the patient.
Bhushan M, Kumar KR. An unusual case of chronic lymphocytic leukemia with trisomy 12 presenting with prolymphocytic transformation and t(8;21)(q22;q22). Clin Case Rep. 2021;9:2504–2506. 10.1002/ccr3.4059
DATA AVAILABILITY STATEMENT
No datasets were generated or analyzed during the current study.
REFERENCES
- 1. Reiniger L, Bödör C, Bognár Á, et al. Richter’s and prolymphocytic transformation of chronic lymphocytic leukemia are associated with high mRNA expression of activation‐induced cytidine deaminase and aberrant somatic hypermutation. Leukemia. 2006;20(6):1089‐1095. [DOI] [PubMed] [Google Scholar]
- 2. Foucar K, Rydell RE. Richter’s syndrome in chronic lymphocytic leukemia. Cancer. 1980;46(1):118‐134. [DOI] [PubMed] [Google Scholar]
- 3. Rana C, Sharma S, Agarwal M. Prolymphocytic and richter’s transformation in peripheral blood: a case report and review of literature. J Hematol. 2014;3(3):86‐88. [Google Scholar]
- 4. Jaffe ES, Harris NL, Stein H, Vardiman JW. WHO classification of tumors of hematopoietic and lymphoid tissues. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, eds. Pathology and genetics of tumors of hematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2001. [Google Scholar]
- 5. Rossi D, Gaidano G. Richter syndrome: pathogenesis and management. Semin Oncol. 2016;43(2):311‐319. [DOI] [PubMed] [Google Scholar]
- 6. Tsimberidou A‐M, O’Brien S, Khouri I, et al. Clinical outcomes and prognostic factors in patients with Richter’s syndrome treated with chemotherapy or chemoimmunotherapy with or without stem‐cell transplantation. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24(15):2343‐2351. [DOI] [PubMed] [Google Scholar]
- 7. Jain P, Keating M, O’Brien S. Richter’s syndrome – update on biology and management. Expert Opin Orphan Drugs. 2014;2(5):453‐463. [Google Scholar]
- 8. Yamamoto K, Yakushijin K, Sanada Y, Kawamoto S, Matsuoka H, Minami H. Coexistent t(8;21)(q22;q22) translocation and 5q deletion in acute myeloid leukemia. J Clin Exp Hematop JCEH. 2015;55(3):181‐185. [DOI] [PubMed] [Google Scholar]
- 9. Al‐Harbi S, Aljurf M, Mohty M, Almohareb F, Ahmed SOA. An update on the molecular pathogenesis and potential therapeutic targeting of AML with t(8;21)(q22;q22.1);RUNX1‐RUNX1T1. Blood Adv. 2020;4(1):229‐238. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Lam K, Zhang D‐E. RUNX1 and RUNX1‐ETO: roles in hematopoiesis and leukemogenesis. Front Biosci J Virtual Libr. 2012;17:1120‐1139. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Sood R, Kamikubo Y, Liu P. Role of RU NX 1 in hematologic malignancies. Blood. 2017;129(15):2070‐2082. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Libermann TA, Pan Z, Akbarali Y, et al. AML1 (CBFα2) cooperates with B cell‐specific activating protein (BSAP/PAX5) in activation of the B cell‐specific BLK gene promoter. J Biol Chem. 1999;274(35):24671‐24676. [DOI] [PubMed] [Google Scholar]
- 13. Grossmann V, Kern W, Harbich S, et al. Prognostic relevance of RUNX 1 mutations in T–cell acute lymphoblastic leukemia. Haematologica. 2011;96(12):1874‐1877. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
No datasets were generated or analyzed during the current study.